The Claim
In adults with established atherosclerosis, 6 months of simvastatin therapy (20–80 mg daily) is associated with a 12% reduction in aortic plaque volume and a 23% reduction in LDL cholesterol, and the degree of plaque regression is directly correlated with the magnitude of LDL cholesterol lowering.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with atherosclerosis, taking simvastatin for six months at doses of 20–80 mg daily is linked to a 12% decrease in aortic plaque volume and a 23% decrease in LDL cholesterol, with greater LDL reduction corresponding to greater plaque reduction.
See the scientific wording
In adults with established atherosclerosis, 6 months of simvastatin therapy (20–80 mg daily) is associated with a 12% reduction in aortic plaque volume and a 23% reduction in LDL cholesterol, with the degree of plaque regression directly correlated to the magnitude of LDL lowering, suggesting lipid reduction plays a key role in early plaque stabilization.
Simvastatin blocks cholesterol production in the liver, which lowers the amount of bad cholesterol in the blood. This creates a pull that draws cholesterol out of the fatty plaques in artery walls. As cholesterol leaves the plaques, they shrink and the artery walls become thinner, reducing the blockage.
What the research says
1 studyIn people with clogged arteries, taking simvastatin for 6 months lowered bad cholesterol by 23% and shrank the plaque by 12%, and the more the cholesterol dropped, the more the plaque got smaller—showing that lowering cholesterol helps clean out the arteries.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.